Alpha cognition announces financial results for the second quarter and six months ended june 2024 and provides corporate update

Vancouver, british columbia--(business wire)--alpha cognition inc. (otcqb: acog) (cse: acog) (“alpha cognition,” or the “company”), a biopharmaceutical company developing novel therapeutics for debilitating neurodegenerative disorders, today reported financial results for the second quarter and six months ended june 30, 2024, and provided a corporate update. “the fda approval of zunveyl represents an important breakthrough for patients with alzheimer's disease. this approval marks a pivotal mom.
ACOG Ratings Summary
ACOG Quant Ranking